Community Bank of Raymore grew its stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 152.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,660 shares of the biopharmaceutical company's stock after purchasing an additional 9,460 shares during the quarter. Community Bank of Raymore's holdings in Bristol-Myers Squibb were worth $1,127,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of the stock. Xponance Inc. raised its stake in Bristol-Myers Squibb by 28.0% during the third quarter. Xponance Inc. now owns 219,534 shares of the biopharmaceutical company's stock worth $15,607,000 after acquiring an additional 47,993 shares during the period. Grimes & Company Inc. raised its stake in Bristol-Myers Squibb by 1.6% during the third quarter. Grimes & Company Inc. now owns 295,464 shares of the biopharmaceutical company's stock worth $21,005,000 after acquiring an additional 4,778 shares during the period. Cliftonlarsonallen Wealth Advisors LLC raised its stake in Bristol-Myers Squibb by 2.2% during the third quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 12,366 shares of the biopharmaceutical company's stock worth $879,000 after acquiring an additional 261 shares during the period. Advocate Group LLC raised its stake in Bristol-Myers Squibb by 9.0% during the third quarter. Advocate Group LLC now owns 97,286 shares of the biopharmaceutical company's stock worth $6,916,000 after acquiring an additional 7,998 shares during the period. Finally, Columbia Asset Management acquired a new stake in Bristol-Myers Squibb during the second quarter worth about $495,000. Institutional investors and hedge funds own 75.51% of the company's stock.
Get Bristol-Myers Squibb alerts:Insiders Place Their Bets
In other news, EVP Ann Powell sold 11,183 shares of the firm's stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.69, for a total transaction of $835,258.27. Following the transaction, the executive vice president now owns 23,043 shares in the company, valued at approximately $1,721,081.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Ann Powell sold 11,183 shares of the firm's stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.69, for a total transaction of $835,258.27. Following the transaction, the executive vice president now owns 23,043 shares in the company, valued at approximately $1,721,081.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Giovanni Caforio sold 240,000 shares of the firm's stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the transaction, the chief executive officer now owns 236,104 shares in the company, valued at approximately $17,625,163.60. The disclosure for this sale can be found here. Insiders own 0.09% of the company's stock.
Bristol-Myers Squibb Trading Up 1.4 %
Bristol-Myers Squibb stock traded up $0.97 during midday trading on Friday, reaching $69.17. The stock had a trading volume of 2,738,663 shares, compared to its average volume of 8,082,146. The firm's fifty day simple moving average is $70.16 and its two-hundred day simple moving average is $72.82. Bristol-Myers Squibb has a twelve month low of $65.28 and a twelve month high of $81.43. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.25 and a quick ratio of 1.14. The firm has a market cap of $145.49 billion, a price-to-earnings ratio of 23.12, a PEG ratio of 1.48 and a beta of 0.46.
Bristol-Myers Squibb (NYSE:BMY – Get Rating) last released its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.71 by $0.11. Bristol-Myers Squibb had a net margin of 13.71% and a return on equity of 51.60%. The company had revenue of $11.41 billion during the quarter, compared to the consensus estimate of $11.20 billion. During the same quarter in the prior year, the firm earned $1.83 EPS. The company's revenue was down 4.8% compared to the same quarter last year. Equities analysts anticipate that Bristol-Myers Squibb will post 8.06 EPS for the current fiscal year.
Bristol-Myers Squibb Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Monday, April 10th will be given a $0.57 dividend. The ex-dividend date of this dividend is Thursday, April 6th. This represents a $2.28 dividend on an annualized basis and a yield of 3.30%. Bristol-Myers Squibb's payout ratio is 77.29%.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on BMY shares. Morgan Stanley raised their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "underweight" rating in a research note on Friday, February 3rd. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $70.00 to $78.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 3rd. Jefferies Financial Group started coverage on shares of Bristol-Myers Squibb in a research note on Monday, March 6th. They issued a "hold" rating and a $62.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, January 17th. They issued an "overweight" rating and a $95.00 price target on the stock. Finally, StockNews.com started coverage on shares of Bristol-Myers Squibb in a report on Thursday, March 16th. They issued a "strong-buy" rating for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $79.69.
Bristol-Myers Squibb Profile
(Get Rating)
Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
Featured Stories
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze, Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- Walmart Shares Jump on Evercore Analyst Upgrade
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.